CompletedNCT00105196
A Study of Aripiprazole in Patients With Major Depressive Disorder
Medication studyAges 18–65United StatesDepression
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 33 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 349
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00105196
- Official title
Show the full official title
A Study of Aripiprazole in Patients With Major Depressive Disorder
Get this study by email
Recruitment & locations
CompletedBirmingham · San Diego · Washington D.C.
29 more locations
- Coral Springs
- Augusta
- Smyrna
- Chicago
- Edwardsville
- Hoffman Estates
- Springfield
- Witchita
- New Orleans
- Baltimore
- Farmington Hills
- Flint
- Minneapolis
- Saint Paul
- Las Vegas
- Charlotte
- Dayton
- Oklahoma City
- Portland
- Media
- Philadelphia
- Charleston
- Columbia
- Austin
- Salt Lake City
- Charlottesville
- Bellevue
- Brown Deer
- Middleton
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole+ ADT and Placebo+ ADT.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
